PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Net Income towards Common Stockholders of -$4.9 million for Q2 2026, down 155.51% year-over-year from $8.8 million in Q2 2025, and down 213.15% quarter-over-quarter from -$1.6 million in Q1 2026.
PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$4.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 155.51% year-over-year to -$4.9 million; the TTM figure through Apr 2026 stood at -$23.2 million (down 199.33% YoY), while the FY2026 annual figure was -$23.2 million, down 199.33% from the prior year.
- Net Income towards Common Stockholders retreated to -$4.9 million in Q2 2026 per PMCB's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $20.6 million in Q3 2024 and bottomed at -$8.4 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$1.3 million across 5 years, with a median of -$2.1 million in 2022.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 1910.91% — and 2025, when it jumped 445.55%.
- PharmaCyte Biotech's Net Income towards Common Stockholders stood at -$1.9 million in 2022, then dropped by 20.08% to -$2.3 million in 2023, then plunged by 31.03% to -$3.0 million in 2024, then slumped by 184.45% to -$8.4 million in 2025, then soared by 42.1% to -$4.9 million in 2026.
- Business Quant data shows PMCB's Net Income towards Common Stockholders at -$4.9 million in Q2 2026, -$1.6 million in Q1 2026, and -$8.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -4.87 Mn |
| Jan 31, 2026 | -1.56 Mn |
| Oct 31, 2025 | -8.42 Mn |
| Jul 31, 2025 | -8.36 Mn |
| Apr 30, 2025 | 8.78 Mn |
| Jan 31, 2025 | -3.05 Mn |
| Oct 31, 2024 | -2.96 Mn |
| Jul 31, 2024 | 20.59 Mn |
| Apr 30, 2024 | -2.54 Mn |
| Jan 31, 2024 | -5.62 Mn |
| Oct 31, 2023 | -2.26 Mn |
| Jul 31, 2023 | -6.78 Mn |
| Apr 30, 2023 | -126,338.00 |
| Jan 31, 2023 | -764,136.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.55 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -814,913.00 |
| Oct 31, 2021 | -986,104.00 |
| Jul 31, 2021 | -1.02 Mn |